Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus ORETON METHYL.
DANOCRINE vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category C
Category C
Androgen/Antigonadotropin
Androgen